The role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal

Basit Öğe Kaydı
dc.contributor.authorJafarova Demirkapu, Mahluga
dc.contributor.authorYananlı, Hasan Raci
dc.contributor.authorKaleli, Melisa
dc.contributor.authorSakalli, Halil Eren
dc.contributor.authorGören, Mehmet Zafer
dc.contributor.authorTopkara, Betilay
dc.date.accessioned2024-10-29T17:43:29Z
dc.date.available2024-10-29T17:43:29Z
dc.date.issued2020
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractOpioids are effective analgaesic agents, but serious adverse effects such as tolerance and withdrawal contribute to opioid dependence and limit their use. Opioid withdrawal is a common occurrence in human opiate addicts that is not life-threatening. Studies have shown that the mesocorticolimbic system, especially the nucleus accumbens, is an important region in drug addiction and adenosine receptors play a modulatory role in the mechanism of action of drug dependence and withdrawal. The aim of this study was to investigate the effects of the selective A1 receptor agonist CPA (N6-cyclopentyladenosine) on withdrawal symptoms, and the concentration of dopamine and noradrenaline in the nucleus accumbens and locomotor activity behaviour during naloxone-precipitated withdrawal in morphine-dependent rats. The local administration of CPA (1.5, 3.0, and 6.0 mmol/L bilateral 250 nL) into the nucleus accumbens decreased the Gellert–Holtzman withdrawal scale, and increased concentrations of dopamine and noradrenaline in the same region during naloxone-induced withdrawal. Our findings suggest that administration of the A1 receptor agonist significantly decreased withdrawal behaviours and increased dopamine and noradrenaline concentrations in opioid withdrawal in a dose-dependent manner. These results demonstrate that adenosine receptors should be examined as a potential mechanism that could be exploited for the treatment of morphine withdrawal. © 2019 John Wiley & Sons Australia, Ltd
dc.description.sponsorshipMarmara University Scientific Research Council, (SAG?C?TUP?141112?0331); Marmara Üniversitesi
dc.identifier.doi10.1111/1440-1681.13224
dc.identifier.endpage560
dc.identifier.issn0305-1870
dc.identifier.issue4en_US
dc.identifier.pmid31808190
dc.identifier.scopus2-s2.0-85080836371
dc.identifier.scopusqualityQ2
dc.identifier.startpage553
dc.identifier.urihttps://doi.org/10.1111/1440-1681.13224
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12414
dc.identifier.volume47
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBlackwell Publishing
dc.relation.ispartofClinical and Experimental Pharmacology and Physiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectadenosine
dc.subjectCPA
dc.subjectdopamine
dc.subjectmorphine
dc.subjectnoradrenaline
dc.subjectnucleus accumbens
dc.titleThe role of adenosine A1 receptors in the nucleus accumbens during morphine withdrawal
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu